Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL)
© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Background: Cumulative data indicate greater tumor response from the addition of IPI (anti-CTLA-4 antibody)...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
11 October 2016
|
| In: |
Annals of oncology
Year: 2016, Jahrgang: 27 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdw379.18 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1093/annonc/mdw379.18 Verlag, kostenfrei, Volltext: https://academic.oup.com/annonc/article/27/suppl_6/1123P/2799942 
|
| Verfasserangaben: | M. Sznol, P.F. Ferrucci, D. Hogg, M. Atkins, P. Wolter, M. Guidoboni, C. Lebbe, J. Kirkwood, J. Schachter, G. Daniels, J. Hassel, J. Cebon, W. Gerritsen, V. Atkinson, L. Thomas, J. McCaffrey, D. Power, J. Jiang, F.S. Hodi, J. Wolchok |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 156533860X | ||
| 003 | DE-627 | ||
| 005 | 20230427142114.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 171114s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/annonc/mdw379.18 |2 doi | |
| 035 | |a (DE-627)156533860X | ||
| 035 | |a (DE-576)495338605 | ||
| 035 | |a (DE-599)BSZ495338605 | ||
| 035 | |a (OCoLC)1340982067 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Sznol, Mario |e VerfasserIn |0 (DE-588)1144313473 |0 (DE-627)1004517947 |0 (DE-576)495338362 |4 aut | |
| 245 | 1 | 0 | |a Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL) |c M. Sznol, P.F. Ferrucci, D. Hogg, M. Atkins, P. Wolter, M. Guidoboni, C. Lebbe, J. Kirkwood, J. Schachter, G. Daniels, J. Hassel, J. Cebon, W. Gerritsen, V. Atkinson, L. Thomas, J. McCaffrey, D. Power, J. Jiang, F.S. Hodi, J. Wolchok |
| 264 | 1 | |c 11 October 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 14.11.2017 | ||
| 520 | |a © The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Background: Cumulative data indicate greater tumor response from the addition of IPI (anti-CTLA-4 antibody) to NIVO (anti-PD-1 antibody) in MEL pts, but with a higher frequency of adverse events (AEs) than observed with either agent alone. The objective of this pooled analysis is to describe the safety profile of NIVO + IPI across MEL studies in which established guidelines for AE management were utilized.Methods: A retrospective safety review was conducted for three phase 1-3 trials in which all MEL pts who received at least 1 dose of the standard regimen, NIVO 1 mg/kg + IPI 3 mg/kg Q3W x 4, then NIVO 3 mg/kg Q2W until disease progression or unacceptable toxicity. Analyses included AEs, select (immune-related) AEs, time to onset and resolution, use... | ||
| 700 | 1 | |a Hassel, Jessica C. |d 1975- |e VerfasserIn |0 (DE-588)129790702 |0 (DE-627)480399069 |0 (DE-576)29783715X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 27(2016,Supplement 6) Artikel-Nummer 1123P, 1 Seite |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL) |
| 773 | 1 | 8 | |g volume:27 |g year:2016 |g supplement:Supplement 6 |a Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL) |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/annonc/mdw379.18 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://academic.oup.com/annonc/article/27/suppl_6/1123P/2799942 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20171114 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 129790702 |a Hassel, Jessica C. |m 129790702:Hassel, Jessica C. |d 910000 |d 911300 |e 910000PH129790702 |e 911300PH129790702 |k 0/910000/ |k 1/910000/911300/ |p 11 | ||
| 999 | |a KXP-PPN156533860X |e 2987183364 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"note":["Gesehen am 14.11.2017"],"id":{"doi":["10.1093/annonc/mdw379.18"],"eki":["156533860X"]},"title":[{"title_sort":"Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL)","title":"Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL)"}],"name":{"displayForm":["M. Sznol, P.F. Ferrucci, D. Hogg, M. Atkins, P. Wolter, M. Guidoboni, C. Lebbe, J. Kirkwood, J. Schachter, G. Daniels, J. Hassel, J. Cebon, W. Gerritsen, V. Atkinson, L. Thomas, J. McCaffrey, D. Power, J. Jiang, F.S. Hodi, J. Wolchok"]},"origin":[{"dateIssuedDisp":"11 October 2016","dateIssuedKey":"2016"}],"person":[{"display":"Sznol, Mario","role":"aut","given":"Mario","family":"Sznol"},{"given":"Jessica C.","role":"aut","family":"Hassel","display":"Hassel, Jessica C."}],"relHost":[{"disp":"Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL)Annals of oncology","physDesc":[{"extent":"Online-Ressource"}],"recId":"320428796","note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"subtitle":"official journal of the European Society for Medical Oncology","title_sort":"Annals of oncology","title":"Annals of oncology"}],"origin":[{"publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","dateIssuedDisp":"1990-","dateIssuedKey":"1990","publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford"}],"part":{"volume":"27","text":"27(2016,Supplement 6) Artikel-Nummer 1123P, 1 Seite","year":"2016"},"id":{"issn":["1569-8041"],"eki":["320428796"],"zdb":["2003498-2"]},"corporate":[{"display":"European Society for Medical Oncology","role":"isb"}],"pubHistory":["1.1990 -"]}],"recId":"156533860X"} | ||
| SRT | |a SZNOLMARIOSAFETYPROF1120 | ||